VERA Earnings & Financial Statements
Vera Therapeutics, Inc.
$26.74
-$0.05(-0.19%)
37
Overall
60
Value
10
Tech
42
Quality
Market Cap
$1.93B
Volume
1.53M
52W Range
$23.05 - $56.05
Target Price
$74.33
VERA earnings and financial statements: Vera Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VERA Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $1.95M | $1.93M | $1.93M | - |
| Operating income | -$315.47M | -$167.17M | -$102.01M | -$90.90M | -$34.40M |
| EBITDA | -$290.17M | -$142.35M | -$89.96M | -$88.06M | -$32.59M |
| Net income | -$299.62M | -$152.15M | -$95.99M | -$89.06M | -$32.61M |
| EPS (diluted) | $-4.66 | $-2.75 | $-2.25 | $-3.35 | $-2.43 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $734.73M | $655.68M | $175.55M | $131.44M | $83.75M |
| Total liabilities | $130.21M | $78.53M | $73.86M | $54.53M | $14.16M |
| Shareholders’ equity | $604.52M | $577.15M | $101.69M | $76.91M | $69.59M |
| Cash and equivalents | $354.73M | $92.65M | $45.68M | $43.46M | $79.67M |
| Long-term debt | $76.76M | $53.16M | $51.27M | $28.64M | $4.92M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$241.10M | -$134.68M | -$92.18M | -$67.60M | -$23.71M |
| Capital expenditure | -$630.0K | -$972.0K | -$63.0K | -$62.0K | -$5.00M |
| Free cash flow | -$241.73M | -$135.65M | -$92.24M | -$67.66M | -$23.71M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VERA | $26.74 | -0.2% | 1.53M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |